These studies generated immune risk scores by comparing Gal-9 level with immune cell TME infiltration, revealing Gal-9 as a biomarker of reoccurrence-free patient survival in SCLC and reduced survival in LCNEC. This evidence concerns the gene LGALS9 and large cell neuroendocrine carcinoma.